Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Alterations in the Cell Cycle of Acute Lymphoblastic Leukemia Cells Resistant to Everolimus

Jordan Basnett, BSc(Hons), Eve Diefenbach, PhD, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, Linda J. Bendall, BSc, PhD

Blood (2014) 124 (21): 3640.

https://doi.org/10.1182/blood.V124.21.3640.3640

Published: 2014

Journal Articles

A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Michael E. Rytting, MD, Farhad Ravandi, MD, Nitin Jain, MD, Jorge E. Cortes, MD, Rebecca Garris, BSc, Mary Ann Richie, RN, Marina Konopleva, MD, PhD, Hongbo Hu, PHD, Jitesh Kawedia, PHD, BS, Kirk Culotta Pharmd, BS, Susan O'Brien, MD, Jordan Basnett, Lianchun Xiao, Xuelin Haung, Linda J. Bendall, BSc, PhD

Blood (2013) 122 (21): 3916.

https://doi.org/10.1182/blood.V122.21.3916.3916

Published: 2013

Journal Articles

Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199

Blood (2013) 122 (21): 3919.

https://doi.org/10.1182/blood.V122.21.3919.3919

Published: 2013

Journal Articles

Evaluation Of Sphingosine Kinase 1 As a Therapeutic Target In B-Lineage Acute Lymphoblastic Leukemia

Craig T Wallington-Beddoe, BSc, MBBS, PhD, FRACP, FRCPA, Stuart M Pitson, BAppSc, PhD, Jason A Powell, BSc, PhD, Kenneth F Bradstock, MBBS, PhD, FRACP, FRCPA, Linda J Bendall, BSc, PhD

Blood (2013) 122 (21): 1426.

https://doi.org/10.1182/blood.V122.21.1426.1426

Published: 2013

Journal Articles

Effects of G-CSF On Acute Lymphoblastic Leukemia.

Jordan Basnett, BSc(Hons), Adam Cisterne, BSc(Hons), Kenneth F Bradstock, MB, PhD, FRACP, FRCPA, Linda J Bendall, BSc, PhD

Blood (2012) 120 (21): 2564.

https://doi.org/10.1182/blood.V120.21.2564.2564

Published: 2012

Journal Articles

Identification of Sphingosine Kinases As Therapeutic Targets in B-Lineage Acute Lymphoblastic Leukemia

Craig T Wallington-Beddoe, BSc, MB BS, FRACP, FRCPA, Kenneth F Bradstock, MB, PhD, FRACP, FRCPA, Linda J Bendall, BSc, PhD

Blood (2012) 120 (21): 1499.

https://doi.org/10.1182/blood.V120.21.1499.1499

Published: 2012

Journal Articles

Mobilizing Agents G-CSF, Cyclophosphamide or AMD3100 (Plerixafor) Have Distinct Effects on Osteoblasts, Hematopoietic Stem Cell Niches, and B-Lymphopoiesis,

Jean-Pierre Levesque, PhD, Linda J. Bendall, BSc, PhD, Allison R Pettit, PhD, Liza Raggatt, PhD, Rebecca Jacobsen, BSc, Valerie Barbier, Bianca Nowlan, Yi Shen, PhD, Natalie A Sims, PhD, Ingrid G Winkler, PhD

Blood (2011) 118 (21): 4005.

https://doi.org/10.1182/blood.V118.21.4005.4005

Published: 2011

Journal Articles

Sphingosine Kinase Inhibition Has Pre-Clinical Activity in Acute Lymphoblastic Leukemia,

Craig T. Wallington-Beddoe, BSc, MBBS, David Ho, BSc, Kenneth Francis Bradstock, MB, PhD, Linda J. Bendall, BSc, PhD

Blood (2011) 118 (21): 3573.

https://doi.org/10.1182/blood.V118.21.3573.3573

Published: 2011

Journal Articles

Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone.,

Jacky Wong, BSc, Robert Welschinger, BSc, PhD, Rana Baraz, BMedSc, Kenneth Francis Bradstock, MB, PhD, Linda J. Bendall, BSc, PhD

Blood (2011) 118 (21): 3575.

https://doi.org/10.1182/blood.V118.21.3575.3575

Published: 2011

Journal Articles

ALL Cells Mobilized by AMD3100 Are More Proliferative, and Remain In the Circulation Longer Than Normal HSC, Enhancing the Action of Vincristine

Linda J. Bendall, BSc, PhD, Robert Welschinger, BSc, PhD, Florian Liedtke, Carole Ford, BSc, PhD, Aileen Dela Pena, BSc, PhD, Julius G Juarez, BSc, PhD, Kenneth Francis Bradstock, MB, PhD

Blood (2010) 116 (21): 2137.

https://doi.org/10.1182/blood.V116.21.2137.2137

Published: 2010

Journal Articles

Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia

Jacky Wong, Robert Welschinger, BSc, PhD, Rana Baraz, Jocelyn Weiss, Ken Bradstock, MB, PhD, Linda J. Bendall, BSc, PhD

Blood (2010) 116 (21): 3258.

https://doi.org/10.1182/blood.V116.21.3258.3258

Published: 2010

Journal Articles

FTY720 Has Potent Anti-Leukemic Effects on Acute Lymphoblastic Leukemia Cells and Results In Caspase Independent Cell Death

Craig T. Wallington-Beddoe, BSc, MBBS, John Hewson, MBBS, Kenneth Francis Bradstock, MB, PhD, Linda J. Bendall, BSc, PhD

Blood (2010) 116 (21): 3260.

https://doi.org/10.1182/blood.V116.21.3260.3260

Published: 2010

Journal Articles

S1P 1 Agonists for Use as Adjunct Mobilizing Agents

Nadia Harun, BSc, (Hons), PhD, Marilyn Thien, BSc, (Hons), PhD, Julius G Juarez, BSc(Hons), PhD, Kenneth Francis Bradstock, MB, PhD, Linda J. Bendall, BSc, PhD

Blood (2010) 116 (21): 826.

https://doi.org/10.1182/blood.V116.21.826.826

Published: 2010

Journal Articles

Combining RAD001 (Everolimus) with Proteasome Inhibitors Bortezomib (Velcade) or MG132 Significantly Enhances Pre-B ALL Cell Death in Vitro.

Philip O. Saunders, MB, MRCP, FRACP, FRCPA, Kenneth F Bradstock, MB, PhD, FRACP, FRCPA, Linda J. Bendall, BSc, PhD

Blood (2009) 114 (22): 2743.

https://doi.org/10.1182/blood.V114.22.2743.2743

Published: 2009

Journal Articles

The JNK Pathway Is a Significant Determinant of Sensitivity to DNA Damaging Agents in Pre-B ALL.

Philip O. Saunders, MB, MRCP, FRACP, FRCPA, Kenneth F Bradstock, MB, PhD, FRACP, FRCPA, Linda J. Bendall, BSc, PhD

Blood (2009) 114 (22): 3786.

https://doi.org/10.1182/blood.V114.22.3786.3786

Published: 2009

Journal Articles

Dose Escalated RAD001 (Everolimus) Enhances Chemosensitivity in Precursor-B Acute Lymphoblastic Leukemia, through a JNK Dependent Suppression of Cell Cycle Checkpoint Regulation.

Philip O. Saunders, MB, MRCP, FRACP, FRCPA, Kenneth F. Bradstock, MB, PhD, FRACP, FRCPA, Linda J. Bendall, BSc, PhD

Blood (2008) 112 (11): 1604.

https://doi.org/10.1182/blood.V112.11.1604.1604

Published: 2008

Journal Articles

The mTOR Inhibitor RAD001 (Everolimus) Improves Survival in Preclinical Models of Primary Human ALL.

Roman Crazzolara, MD, Adam Cisterne, BSc, Marilyn Thien, Bsc, PhD, John Hewson, MD, Kenneth Francis Bradstock, MD, PhD, Linda J. Bendall, BSc, PhD

Blood (2007) 110 (11): 856.

https://doi.org/10.1182/blood.V110.11.856.856

Published: 2007

Journal Articles

The Wnt Pathway Modulates Expression of Growth and Survival Genes in Acute Lymphoblastic Leukemia Cells.

Naveed I. Khan, BSc (Hons), Kenneth Francis Bradstock, MBBS PhD, Linda J. Bendall, BSc, PhD

Blood (2006) 108 (11): 1850.

https://doi.org/10.1182/blood.V108.11.1850.1850

Published: 2006

Journal Articles

CXCR4 Antagonists Mobilize Acute Lymphoblastic Leukemia Cells into the Peripheral Blood and Inhibit Engraftment in Mice.

Julius Juarez, BSc, John Hewson, MD, Adam Cisterne, BSc, Rana Baraz, BSc, Kenneth F. Bradstock, MD, PhD, Linda J. Bendall, BSc PhD

Blood (2005) 106 (11): 4592.

https://doi.org/10.1182/blood.V106.11.4592.4592

Published: 2005

Journal Articles

The Wnt/β-Catenin Pathway Promotes Growth and Survival of Acute Lymphoblastic Leukaemia (ALL) Cells In Vitro.

Naveed I. Khan, BSc, Kenneth F. Bradstock, MD, PhD, Linda J. Bendall, BSc PhD

Blood (2005) 106 (11): 4553.

https://doi.org/10.1182/blood.V106.11.4553.4553

Published: 2005

NARROW

Alterations in the Cell Cycle of Acute Lymphoblastic Leukemia Cells Resistant to Everolimus

A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199

Evaluation Of Sphingosine Kinase 1 As a Therapeutic Target In B-Lineage Acute Lymphoblastic Leukemia

Effects of G-CSF On Acute Lymphoblastic Leukemia.

Identification of Sphingosine Kinases As Therapeutic Targets in B-Lineage Acute Lymphoblastic Leukemia

Mobilizing Agents G-CSF, Cyclophosphamide or AMD3100 (Plerixafor) Have Distinct Effects on Osteoblasts, Hematopoietic Stem Cell Niches, and B-Lymphopoiesis,

Sphingosine Kinase Inhibition Has Pre-Clinical Activity in Acute Lymphoblastic Leukemia,

Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone.,

ALL Cells Mobilized by AMD3100 Are More Proliferative, and Remain In the Circulation Longer Than Normal HSC, Enhancing the Action of Vincristine

Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia

FTY720 Has Potent Anti-Leukemic Effects on Acute Lymphoblastic Leukemia Cells and Results In Caspase Independent Cell Death

S1P 1 Agonists for Use as Adjunct Mobilizing Agents

Combining RAD001 (Everolimus) with Proteasome Inhibitors Bortezomib (Velcade) or MG132 Significantly Enhances Pre-B ALL Cell Death in Vitro.

The JNK Pathway Is a Significant Determinant of Sensitivity to DNA Damaging Agents in Pre-B ALL.

Dose Escalated RAD001 (Everolimus) Enhances Chemosensitivity in Precursor-B Acute Lymphoblastic Leukemia, through a JNK Dependent Suppression of Cell Cycle Checkpoint Regulation.

The mTOR Inhibitor RAD001 (Everolimus) Improves Survival in Preclinical Models of Primary Human ALL.

The Wnt Pathway Modulates Expression of Growth and Survival Genes in Acute Lymphoblastic Leukemia Cells.

CXCR4 Antagonists Mobilize Acute Lymphoblastic Leukemia Cells into the Peripheral Blood and Inhibit Engraftment in Mice.

The Wnt/β-Catenin Pathway Promotes Growth and Survival of Acute Lymphoblastic Leukaemia (ALL) Cells In Vitro.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only